The Arthritis Monoclonal Antibodies Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Arthritis Monoclonal Antibodies Market?
The market size for arthritis monoclonal antibodies has seen significant expansion in recent years. It is projected to increase from $58.09 billion in 2024 to $62.29 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 7.2%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Arthritis Monoclonal Antibodies Industry?
The Arthritis Monoclonal Antibodies market is anticipated to reach a total value of $83.76 billion by the year 2029, with a compound annual growth rate (CAGR) of 7.7%.
Download Your Free Sample of the 2025 Arthritis Monoclonal Antibodies Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Arthritis Monoclonal Antibodies Market?
The key drivers in the arthritis monoclonal antibodies market are:
• Rising interest in combination therapies
• Expansion of indications for arthritis monoclonal antibodies
• Increased patient preference for these treatments
• Enhanced healthcare spending globally
Global Market Segmentation: Identifying Major Arthritis Monoclonal Antibodies Industry Segments
The arthritis monoclonal antibodies market covered in this report is segmented –
1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima
2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications
3) By End-Use: Hospitals, Research Institutes, Other End-Users
Pre-order the 2025 Arthritis Monoclonal Antibodies Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Arthritis Monoclonal Antibodies Market?
The key trends in the arthritis monoclonal antibodies market are:
• The advent of biosimilars and biobetters is becoming a key trend.
• The demand for targeted therapies is on a significant rise.
• Homecare administration of monoclonal antibodies is emerging as a significant trend.
• Real-world evidence, cost, and access considerations are increasingly shaping the market.
Who Are the Top Competitors & Leading Players in the Arthritis Monoclonal Antibodies Market?
Major companies in the arthritis monoclonal antibodies market are:
• Johnson & Johnson
• Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer Inc.
• AbbVie Inc.
• Amgen Inc.
• Genentech Inc.
• GlaxoSmithKline plc.
• AstraZeneca plc
• Bristol Myers Squibb
• Eli Lilly and Company
• Thermo Fisher Scientific Inc.
• Sanofi SA
• Daiichi Sankyo Company Ltd.
• Seattle Genetics
• Teva Pharmaceutical Industries Ltd.
• Shanghai Junshi Biosciences Co. Ltd.
• GenScript Biotech Corporation
• Sigma-Aldrich Co. LLC
• AbGenomics Corp.
• ADC Therapeutics SA
• Agensys Inc.
• Alexion Pharmaceuticals Inc.
• ALMAC Group Ltd.
• Ambrx Inc.
• Astellas Pharma Inc.
• Celgene Corporation
• Celldex Therapeutics Inc.
• Boehringer Ingelheim International GmbH
• Celltrion Inc.
• HanAll Biopharma Co. Ltd.
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corporation
• Regeneron Pharmaceuticals Inc.
• Samsung Bioepis Co. Ltd.
Regional Dominance: Which Area Leads the Global Arthritis Monoclonal Antibodies Market?
The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada
